Torsades de pointes

Articolo redatto e revisionato del Dott. Luca Moretti

Torsades de pointes is a form of polymorphic ventricular tachycardia that develops in the setting of prolonged repolarization and shows cyclic variation in the axis and amplitude of the QRS complexes, with apparent rotation around the isoelectric line. Episodes may terminate spontaneously, recur in runs, or degenerate into ventricular fibrillation. Recognition is not based solely on the appearance of the arrhythmia: the QT interval preceding the event, the initiating sequence, and the clinical circumstances are essential for correctly identifying its mechanism.

The acquired form often emerges from the interaction among drugs, electrolyte abnormalities, bradycardia, and individual susceptibility. Congenital forms belong to the spectrum of long-QT syndromes and may present at different ages and under different circumstances. The true incidence is difficult to estimate because self-limited episodes may go unrecorded and a cardiac arrest may be documented only once ventricular fibrillation has developed. Pharmacovigilance reports are also influenced by concomitant exposures and differences in diagnostic recognition.

Distinguishing it from polymorphic ventricular tachycardia with a normal QT interval has immediate consequences. Treatment of pause-dependent torsades is not the same as treatment of an ischemic or catecholaminergic arrhythmia. The historical term short-coupled torsades has also been used for conditions without QT prolongation, which must be considered separately. In this monograph, the term refers to the classic form associated with prolonged repolarization, with attention to diagnosis, predisposing factors, and prevention of recurrence.

Prolonged repolarization and the mechanism of initiation

The duration of the ventricular action potential depends on the balance between depolarizing and repolarizing currents. Reduction in potassium currents or an increase in inward currents may delay recovery of excitability and promote early afterdepolarizations, which occur before the action potential has fully ended. If they reach a sufficient threshold, they can generate a premature beat. QT prolongation alone, however, does not describe the entire vulnerability: how repolarization varies between regions and over time also matters.

Repolarization reserve describes the ability of partially redundant currents to compensate for a perturbation. A single drug may be tolerated while this reserve is adequate and become proarrhythmic when hypokalemia, bradycardia, myocardial disease, or a predisposing genetic variant is added. This model explains why the same dose does not produce the same risk in every person and why an episode may appear after a period of apparent tolerance. Investigation of the cause must therefore reconstruct the combination of factors.

Heterogeneity of repolarization creates regions with different recovery times. A premature impulse may encounter excitable tissue adjacent to areas that are still refractory and initiate unstable propagation. Polymorphism results from the evolving activation wavefronts, while cyclic variation of the axis produces the twisting appearance. A single fixed anatomical circuit such as that seen in scar-related monomorphic tachycardia is not required; the dynamics of refractoriness and conduction play a central role.

In acquired forms, a pause may accentuate prolongation of repolarization in the following beat and facilitate initiation. A short-long-short sequence is common, in which a premature beat is followed by a pause and then by a new early depolarization. The description should be based on the actual recording because not every episode shows the complete sequence and not every alternation of intervals produces torsades. Sinus bradycardia, atrioventricular block, and pauses after termination of an arrhythmia may create favorable conditions.

Many drugs act on the rapid delayed rectifier potassium current, IKr, mediated by the channel commonly identified as hERG. The degree of QT prolongation, however, does not translate into an identical torsades risk for every molecule. Amiodarone, for example, may prolong the QT interval with a generally lower propensity for torsades than other antiarrhythmic drugs, although the risk is not eliminated. Effects on multiple currents, repolarization distribution, and heart rate contribute to these differences and prevent classification based only on milliseconds.

In inherited forms, defects in ionic currents alter the relationship between repolarization and triggers. Abnormalities in KCNQ1, KCNH2, and SCN5A are important causes of the most common syndromes but do not exhaust their heterogeneity. Exercise, emotion, sudden stimuli, or rest may have different importance according to phenotype. Pause dependence, particularly evident in many acquired cases, should not be assumed to be a universal mechanism for every event associated with congenital long-QT syndrome.

Predisposing factors and acquired or congenital causes

Antiarrhythmic drugs with the potential to prolong repolarization include sotalol, dofetilide, and class Ia agents such as quinidine and procainamide. Drugs prescribed for other indications may also contribute, including some macrolides, fluoroquinolones, antipsychotics, antidepressants, and methadone. Membership in a drug class does not imply identical risk for every agent. Assessment must consider the specific drug, dose, route of administration, interactions, and patient characteristics rather than replacing this analysis with a generic list of prohibited medications.

Interactions may be pharmacodynamic, when multiple substances interfere with repolarization, or pharmacokinetic, when one therapy increases exposure to another. Worsening renal function is particularly important for renally eliminated drugs; hepatic changes and metabolic inhibition matter for other agents. A dose change is not required for risk to increase: diarrhea, vomiting, dehydration, or a new prescription may alter a previously stable balance. The history also includes over-the-counter medications and intermittent use.

Hypokalemia reduces repolarization reserve and may amplify pharmacologic blockade of currents. Hypomagnesemia adds vulnerability, while hypocalcemia may contribute to QT prolongation through different mechanisms. The clinical effect depends on the combination and rapidity of the abnormalities. A normal serum magnesium concentration does not exclude benefit from intravenous magnesium in torsades because the therapeutic effect is not simply equivalent to correction of a measured deficiency.

Female sex, older age, heart disease, heart failure, and a history of previous QT prolongation may increase susceptibility in different settings. Bradycardia and conduction disorders have a specific role when they make the arrhythmia pause dependent. Risk often results from accumulation of moderate factors rather than a single extreme abnormality. The presence of an apparently acquired cause does not exclude genetic predisposition, and an episode disproportionate to the exposure may justify targeted further evaluation.

Congenital long-QT syndrome may be recognized after syncope, cardiac arrest, family screening, or an electrocardiographic finding. Incomplete penetrance and variability of the QT interval may allow an inconclusive ECG between events. Diagnosis integrates repeated measurements, symptoms, family history, possible dynamic testing, and genetics. A variant of uncertain significance must not be equated with a diagnosis, whereas a negative test does not eliminate every possibility of inherited disease when the phenotype is convincing.

Acute conditions such as neurologic injury, Takotsubo syndrome, and systemic illnesses may be accompanied by prolonged repolarization. In these patients, drugs and metabolic abnormalities may overlap with the primary process. The QT interval measured after cardiac arrest or during temperature changes may also be transiently altered. Evaluation should distinguish the baseline value, the effect of the acute event, and the effect of therapies because this distinction affects prognosis and decisions after stabilization.

Electrocardiographic diagnosis and clinical assessment

A typical recording shows polymorphic tachycardia with progressive variation in QRS polarity and amplitude, often in episodes that begin and terminate spontaneously. The rate is generally high and separation between complexes may become difficult. The twisting appearance may not be evident in every lead or in a very short run. Diagnosis therefore requires preservation of the tracing before and after the episode, not only the most striking portion of the arrhythmia.

The QT interval should be measured manually when the automated value appears doubtful or is being used to guide an important decision. The beginning of the QRS and the end of the T wave should be identified in a suitable lead, avoiding inappropriate inclusion of a distinct U wave. T-U fusion, bifid T waves, and low amplitude make measurement more difficult. Representative beats should be used and a consistent method maintained in serial comparisons, without assigning excessive significance to small technique-related differences.

Heart-rate correction formulas have limitations. Bazett's formula tends to overcorrect at high rates and undercorrect at low rates; other formulas may be preferable in certain settings. With a wide QRS, part of the QT interval results from prolonged depolarization, and assessment of repolarization requires specific interpretation, potentially including the JT interval. It is incorrect to compare an automated number obtained during bundle branch block with a threshold without accounting for QRS duration.

A QTc above 500 milliseconds is an important marker of increased vulnerability in many settings, but it is not an absolute boundary separating safety from danger. A substantial increase from baseline, marked T-U distortion, T-wave alternans, ectopy, and pauses may add information. No single index replaces clinical integration. The definition of congenital long QT also requires its own diagnostic criteria and is not identical to the threshold used to monitor a therapy.

The differential diagnosis includes ischemic polymorphic tachycardia with a normal QT interval, catecholaminergic arrhythmias, pre-excited atrial fibrillation, and artifact. An ECG obtained only after drug administration or resuscitation may lead to erroneous attribution of a long QT interval as the origin of the episode. A short-coupled trigger without preceding prolongation of repolarization suggests a different condition. Correct classification is practical: it prevents use of pause-dependent strategies in an adrenergic disease or of antiarrhythmic drugs that worsen the QT interval in torsades.

Clinical assessment includes hemodynamic stability, electrolytes, renal function, medications, and possible acute causes. Echocardiography defines ventricular function and structural disease; coronary investigations, magnetic resonance imaging, or genetic testing are selected according to suspicion. Convulsive syncope and sudden falls may be arrhythmic manifestations and require accurate reconstruction. Lack of a recording of the event does not make a markedly abnormal QT interval with a compatible history irrelevant, but certainty of diagnosis and clinical probability must remain distinct.

Termination of the episode and control of immediate recurrences

Persistent torsades with severe hemodynamic compromise requires defibrillation because QRS variability may prevent reliable synchronization. In the absence of a pulse, cardiopulmonary resuscitation and treatment of a shockable rhythm are performed. Confirmation of the etiology or availability of electrolyte results is not awaited. An episode that has already terminated does not require a shock; the urgency is instead to prevent a new run or degeneration while maintaining monitoring and immediate intervention capability.

Withdrawal of the responsible drugs should be accompanied by investigation of interactions and correction of metabolic abnormalities. Stopping a single molecule may be insufficient if others continue to affect repolarization or slow its elimination. The duration of risk also depends on half-life, metabolites, and organ function, so normalization is not necessarily immediate. Essential therapies should be reassessed together with possible alternatives, with a plan that includes indication, risk, and monitoring.

Intravenous magnesium sulfate is a central treatment for torsades even when the initial serum magnesium concentration is normal. It may reduce the tendency to recur without clearly shortening the QT interval; lack of a rapid interval change therefore does not mean lack of efficacy. Administration and repeat dosing are adapted to the clinical situation, renal function, and the protocol being used. Monitoring includes blood pressure, rhythm, and possible effects of administration, particularly in frail patients or those with reduced elimination.

Potassium, magnesium, and calcium are corrected when abnormal, avoiding both persistent deficiency and uncontrolled supplementation. In acquired torsades, potassium is often maintained in the high-normal range, with repeated measurements and attention to renal function. Correction should not be viewed as an isolated intervention: a drug still present in the body and significant bradycardia may maintain risk even after serum values have recovered. Treatment simultaneously addresses multiple components of the mechanism.

When pause-dependent episodes persist, increasing the heart rate may prevent pauses and reduce prolongation of the action potential. Temporary pacing is tailored to the clinical response; isoproterenol may be used in selected cases of acquired long QT, including as a temporary measure while pacing is organized. It is not a universal solution because adrenergic stimulation may worsen ischemia or catecholaminergic arrhythmias and may be inappropriate in some congenital forms. The choice requires a reasonably established diagnosis of the mechanism.

Automatic use of amiodarone or other antiarrhythmic drugs that prolong repolarization may worsen torsades and should be avoided as an undifferentiated response to every polymorphic tachycardia. In selected situations, pharmacologic strategies that reduce depolarizing currents may be useful, but they do not replace correction of causal factors. Sedation and pain control may reduce overall instability, while intensive support and electrophysiology consultation become necessary in refractory recurrences. Electrical and causal treatment remain complementary.

Definitive treatment and prevention of proarrhythmic exposure

In acquired torsades, long-term prevention depends on removing the mechanism that produced the long QT interval. The suspected drug, any cofactors, and the response to withdrawal should be documented, while keeping a plausible relationship distinct from proven causality. Re-exposure to the same combination may be dangerous and should be avoided when the link is convincing. Choosing alternatives is not limited to nominal substitution: indication, metabolism, excretion, and residual interactions must be considered.

Assessment of the QT interval after correction helps evaluate reversibility. Persistent prolongation, a history of prior syncope, or significant family history may suggest an unrecognized predisposition. Even a normalized QT interval does not exclude all genetic susceptibility, but it does not automatically justify an extensive panel in the absence of clinical indicators. Specialist consultation determines when to investigate the phenotype further and how to interpret results, avoiding conversion of uncertain variants into definitive diagnoses.

In congenital syndromes, beta-blockers are a cornerstone of therapy, with the agent and intensity adapted to phenotype and tolerability. Nadolol and propranolol have important roles in many specialist pathways. Adherence, coverage throughout daily activity, and avoidance of abrupt withdrawal are substantial aspects of treatment. Benefit cannot be inferred solely from QT shortening because control of adrenergic response and triggers has a role independent of the interval value.

Additional therapies are selected according to subtype and response. Mexiletine may be useful in specific forms associated with increased late sodium current, with electrocardiographic and clinical verification of the response. Left cardiac sympathetic denervation may be considered when risk or recurrences remain significant despite appropriate therapy or when that therapy is not tolerated. These strategies require dedicated expertise and do not represent an identical mandatory sequence for every long-QT syndrome.

An implantable cardioverter-defibrillator is evaluated according to history of cardiac arrest, events during therapy, residual risk, and the possibility of controlling the cause. An episode attributed to a completely reversible factor does not automatically carry the same indication as persistent inherited disease. The device can treat the arrhythmia but cannot prevent its initiation, so medications and causal measures remain necessary. In patients with bradycardia or conduction disorders, pacing may also be relevant and must be distinguished from the defibrillation function.

In pacemaker or defibrillator recipients, programming should avoid pauses capable of promoting the arrhythmia when the mechanism has been documented. Lower rate, algorithms that allow slowing, and behavior after premature beats or arrhythmia termination may influence cycle sequences. The presence of a device alone does not guarantee protection from pause-dependent torsades. Review of stored tracings and settings allows episodes to be linked to the system's actual behavior.

Prognosis, monitoring, and long-term management

Prognosis depends on true reversibility, substrate, and history of events. Drug-induced torsades recognized early may resolve after removal of the exposure and cofactors, whereas congenital disease requires ongoing protection. Spontaneous termination of a run does not demonstrate benignity: the same vulnerability may produce a longer subsequent episode. Risk must therefore be assessed according to cause and context without assigning reassuring significance to duration alone.

In-hospital monitoring is maintained until the electrocardiographic picture, electrolytes, and drug exposure permit appropriate management outside continuous monitoring. There is no universal observation interval suitable for substances with different half-lives and elimination pathways. New pause-dependent ectopy, T-U distortion, or additional runs indicate ongoing vulnerability. Absence of episodes for a few hours is not sufficient if the responsible drug persists or bradycardia has not been corrected.

During follow-up, medication review is a concrete preventive measure. Every new therapy should be assessed in the context of the others, with attention to renal function, dose, and electrolytes. Gastrointestinal illness, major dietary restriction, or diuretics may alter risk even without new QT-prolonging drugs. The patient should receive clear information about the history of the event and how to communicate it to different clinicians so that an apparently unrelated prescription does not recreate the original combination.

In inherited forms, evaluation of family members is guided by the phenotype and any pathogenic variant. A variant of uncertain significance should not be used as the sole criterion to label relatives, whereas a solid clinical diagnosis may require screening even without a conclusive genetic result. Age, growth, pregnancy, and the postpartum period may alter the risk context and therapeutic needs according to subtype. The plan should be updated without indiscriminately applying observations that are valid only for certain forms.

Physical activity, sport, work, and anesthetic procedures require individualized assessment. Preparation for a procedure should include medication management, electrolytes, and appropriate monitoring, avoiding uncoordinated discontinuations or additions. A single favorable test is not a permanent guarantee, but neither does the name of the syndrome impose the same limitation on every person. The decision should integrate documented risk, treatment, planned activity, and the availability of assistance in the event of an episode.

The quality of management is measured by prevention of recurrence, safety of therapy, and preservation of daily life. Fear of syncope and psychological consequences of shocks may require specific support. Retaining ECGs, medication documentation, and the rationale for decisions helps distinguish over time a new exposure, persistent predisposition, and an event caused by another mechanism. In torsades de pointes, correct identification of repolarization and the initiating sequence remains the prerequisite for treatment.